Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Starpharma Signs Collaborative Research Agreement with Stiefel Laboratories, Inc.

Abstract:
Starpharma today announced the signing of a collaborative research agreement with Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, to apply Starpharma's dendrimer nanotechnology to certain drugs used dermally. Stiefel Laboratories has five Global Research and Development Centers and has products marketed in more than 100 countries around the world.

Starpharma Signs Collaborative Research Agreement with Stiefel Laboratories, Inc.

MELBOURNE, Australia | Posted on December 3rd, 2007

The collaboration will apply Starpharma's dendrimer technology to deliver drugs through the skin with the aim of improving the effectiveness and tolerability of certain dermal treatments. Under the terms of the agreement Starpharma will receive staged payments on successful completion of technical milestones within the collaborative project. The agreement also deals with commercialization rights arising from the collaboration. Confidentiality provisions restrict disclosure of further details of the collaborative program and agreement.

"This agreement is significant for Starpharma in that it expands the applications for dendrimer technology to a new and potentially lucrative drug-delivery area. We consider drug delivery applications of dendrimers to represent a highly attractive commercial opportunity and we are delighted to be working with such a strong international partner in dermatology," commented Starpharma CEO, Dr. Jackie Fairley.

This is the fourth agreement signed by Starpharma this year to develop commercial applications for its dendrimer technology. Starpharma also has dendrimer drug delivery programs underway in cancer and protein therapeutics.

According to Gavin Corcoran, M.D., Senior Vice President, Global Research & Development for Stiefel Laboratories, this development agreement is aligned with Stiefel's commitment to advancing the field of dermatology.

"Our partnership with Starpharma and the resulting agreement will add to Stiefel's innovative technology offerings including the VersaFoam(TM), EPX(TM) and dimethylisosorbide (DMI) vehicles that have greatly enhanced topical drug delivery," said Corcoran.

In February 2007 Starpharma entered into a worldwide exclusive license and supply agreement with EMD Biosciences, part of Merck KGaA's Performance and Life Science Chemicals division. Under the terms of that agreement, Starpharma supplies EMD with Priofect(R) transfection reagents based on Priostar(R) proprietary dendrimers for the DNA and siRNA transfection research markets. Additionally two co-development agreements have recently been signed in relation to condom coating applications of Starpharma's lead product VivaGel(R). One of the agreements is with SSL International Plc, the makers of Durex(R), and a second with an undisclosed condom manufacturer. VivaGel(R) is a vaginal microbicide being developed under IND to prevent the transmission of HIV and genital herpes during sexual intercourse.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX: SPL; Pink Sheets: SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) (clindamycin, 1% - benzoyl peroxide, 5%) Topical Gel; Evoclin(R) (clindamycin phosphate, 1%) Foam; Luxiq(R) (betamethasone valerate, 0.12%) Foam; MimyX(R); Olux(TM) (clobetasol propionate, 0.05%) Foam; Olux-E(TM) (clobetasol propionate, 0.05%) Foam; Soriatane(R) (acitretin) CK CONVENIENCE KIT(TM); Verdeso(TM) (desonide, 0.05%) Foam; Brevoxyl(R) (benzoyl peroxide, 4% or 8%) Creamy Wash packaged in the convenient new BREVOXYL Acne Wash Kit; Extina(R) (ketoconazole, 2%) Foam; Oilatum(R); Physiogel(R); Stieprox(R) (ciclopirox olamine); REVALESKIN(TM); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit http://www.stiefel.com/ .

For more information, please click here

Contacts:
Media
Rebecca Wilson
Buchan Consulting
Tel: +61 2 9237 2800
Mob: +61 417 382 391


Philippa Harris
Buchan Consulting
Tel: +61 2 9237 2811
Mob: +61 408 465 800


Starpharma
http://www.starpharma.com/

Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704

Ben Rogers
Company Secretary
+61 3 8532 2702

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Announcements

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Alliances/Trade associations/Partnerships/Distributorships

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B October 6th, 2016

Research partnerships

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Novel silicon etching technique crafts 3-D gradient refractive index micro-optics November 28th, 2016

Single photon converter -- a key component of quantum internet November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project